BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24721323)

  • 1. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
    Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
    Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC).
    Zhang BY; Wang YM; Gong H; Zhao H; Lv XY; Yuan GH; Han SR
    Int J Clin Exp Pathol; 2015; 8(1):25-37. PubMed ID: 25755690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
    Zhang N; Sun P; Jin H; Yang Y; Zhao Q; Zhou L; Guo L; Yang X; Lu L
    Anticancer Drugs; 2020 Aug; 31(7):702-708. PubMed ID: 32701251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of cytotoxic effect of the combination of a pyridinyl carboxamide derivative and oxaliplatin on NCI-H1299 human non-small cell lung carcinoma cells.
    Teixeira SF; de Azevedo RA; Silva AC; Braga RC; Jorge SD; Barbuto JAM; Andrade CH; Ferreira AK
    Biomed Pharmacother; 2016 Dec; 84():1019-1028. PubMed ID: 27768927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
    Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
    Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
    Gavrilov V; Lavrenkov K; Ariad S; Shany S
    Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.
    Azijli K; van Roosmalen IA; Smit J; Pillai S; Fukushima M; de Jong S; Peters GJ; Bijnsdorp IV; Kruyt FA
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1273-83. PubMed ID: 24744163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
    Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles.
    Rossi A; Di Maio M
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):653-60. PubMed ID: 27010977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
    Wu YF; Ou CC; Chien PJ; Chang HY; Ko JL; Wang BY
    Phytomedicine; 2019 Mar; 56():94-102. PubMed ID: 30668358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
    Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
    BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
    Mack PC; Gandara DR; Lau AH; Lara PN; Edelman MJ; Gumerlock PH
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):337-48. PubMed ID: 12721762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
    Zhu K; Fang W; Chen Y; Lin S; Chen X
    Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
    Iwasa T; Okamoto I; Takezawa K; Yamanaka K; Nakahara T; Kita A; Koutoku H; Sasamata M; Hatashita E; Yamada Y; Kuwata K; Fukuoka M; Nakagawa K
    Br J Cancer; 2010 Jun; 103(1):36-42. PubMed ID: 20517311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY; Xu YP; Jin W; Lou LG
    Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
    Hu Z; Zeng Q; Zhang B; Liu H; Wang W
    Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.